FATE · Fate Therapeutics Inc

Track FATE — free

$2.32 +0.02 (+0.87%) At close · Oct 2

Rebalance outlook locked

Market Cap

$281.58M

119.82M

Volume · Oct 2 658.02K Avg daily vol (3M) 1.92M

Up next

Latest filing: 10-Q

filed Aug 13, 2026

Q1 2024 earnings call transcript

call held May 9, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$6.49M

Trailing 12 months

Net income (TTM)

−$126.00M

Trailing 12 months

Revenue growth YoY

+9.2%

Year over year

Operating margin

-2,058.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-37.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1.6%

Year over year · more shares

Price change (1Y)

+84.0%

Trailing year

Short interest

7.8%

Latest settlement · 10.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bearish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +25%

above

Price vs 50-day avg −6%

below

RSI (14) 42

neutral

MACD trend Negative

52-week position 63%

mid-range

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Strong

1-month return −4%

trailing

6-month return +77%

trailing

YTD return +137%

this year

Relative strength +65%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Distributing

-1% holders QoQ · +31 funds added

Insider flow Distributing

Net -$203.5K over 90 days · 100% sells

Short interest Rising

7.83% of float · ▲ +3.0% MoM · 10.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

156 holders — mid 3-yr range

Squeeze score 67

elevated · 0–100

Fundamentals

Fair

Revenue growth −51%

Y/Y

EPS growth +30%

Y/Y

Free cash flow $-112.0M

Balance sheet $175.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 92%

annualized · 1-yr

Max drawdown −42%

past year

ATR 6.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+25% Bullish

Price vs 50-day avg

−6% Bearish

RSI (14)

42 Neutral

MACD trend

Negative Bearish

52-week position

63% Neutral

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Distributing

-1% holders QoQ · +31 funds added

Insider flow Distributing

Net -$203.5K over 90 days · 100% sells

Short interest Rising

7.83% of float · ▲ +3.0% MoM · 10.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

156 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $2 · 63% Range high $3

vs 200-day avg +25% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FATE Fate Therapeutics Inc this stock	$281.58M	+136.7%	-51.2%	—	7.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

156

% held: 60.0%
Net QoQ: -2.3M sh
Top holder: Redmile Group, LLC

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

9.4M

Days to cover: 10.5d
Change: +275.4K sh

View

Short Volume

Short vol %

56%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

6.1K

Value: $15.2K
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

50.4%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$203.5K

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Jan 31, 2023

View

Financials

Revenue (FY)

$6.6M

Net income (FY): $-136.3M
EPS diluted: $-1.15

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 28, 2026
This year: 10

View

Proposed Sales

Value

$108.1K

Shares: 43.9K
Filed: Aug 4, 2026

View

Exempt Offerings

Offering

$50.0M

Filed: Jul 6, 2020

View

Earnings & Events

Webcasts

Last webcast

May 9, 2024

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
FATE	-1.3%	-4.1%	+77.1%	-2.1%	+136.7%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-1.1%	-3.7%	+64.9%	-3.0%	+123.9%

Key facts CIK 1434316 CUSIP 31189P102 13F (30d) 3 filings 3 filers Visit website Investor relations

FATE · Fate Therapeutics Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance